Azelaic Acid

What is it?

Azelaic acid is a naturally occurring C9 dicarboxylic acid (nonanedioic acid) produced by the yeast Malassezia furfur on human skin and also found in grains such as wheat, rye, and barley. In dermatology, azelaic acid occupies a rare position as a multi-mechanism active ingredient with simultaneous anti-inflammatory, antibacterial, antioxidant, and anti-melanogenic properties — all delivered with remarkably low irritation potential compared to other acids. Its antibacterial action targets Propionibacterium acnes (Cutibacterium acnes) through inhibition of bacterial protein synthesis, while its anti-inflammatory properties stem from suppression of reactive oxygen species (ROS) production, inhibition of neutrophil-generated free radicals, and downregulation of NF-kappaB-mediated pro-inflammatory cytokine release including IL-1beta, IL-6, and TNF-alpha. Azelaic acid's brightening mechanism is distinct from most other depigmenting agents. Rather than broadly suppressing melanocyte function, azelaic acid selectively inhibits tyrosinase — the rate-limiting enzyme in melanin biosynthesis — and also disrupts mitochondrial oxidoreductase activity in hyperactive melanocytes. Crucially, this selectivity means azelaic acid preferentially targets abnormally active melanocytes while leaving normally functioning melanocytes relatively unaffected, making it one of the safest long-term options for hyperpigmentation in all Fitzpatrick skin types, including darker skin tones where the risk of paradoxical hypo- or hyperpigmentation from other treatments is highest. Azelaic acid is available at 10% over the counter and 15-20% by prescription (Finacea gel 15%, Azelex cream 20%). It is one of very few prescription-strength acne and rosacea treatments classified as FDA Pregnancy Category B, making it one of the safest active ingredients available for pregnant and breastfeeding patients. Its pH-independent mechanism (unlike AHAs/BHAs which require low pH) and compatibility with most other actives make it highly versatile in combination protocols.

How It Works

1. 1

   Tyrosinase Inhibition in Hyperactive Melanocytes

   Azelaic acid selectively suppresses tyrosinase — the rate-limiting enzyme in melanin synthesis — in abnormally active melanocytes, reducing hyperpigmentation while leaving normal melanocytes unaffected.

2. 2

   Antibacterial Protein Synthesis Disruption

   Inhibits bacterial protein synthesis in C. acnes and disrupts the microbial biofilm that perpetuates inflammatory acne lesions, reducing the bacterial load that triggers breakout-associated inflammation.

3. 3

   Reactive Oxygen Species Scavenging

   Neutralizes ROS generated by neutrophils and UV exposure, breaking the oxidative stress cycle that drives rosacea flares and post-inflammatory pigmentation — complementing PDRN's cytokine-level anti-inflammatory action.

4. 4

   NF-kappaB Pathway Suppression

   Downregulates NF-kappaB-mediated release of IL-1beta, IL-6, and TNF-alpha, operating in parallel with PDRN's adenosine A2A receptor pathway for compounded anti-inflammatory control across multiple signaling cascades.

Role in PDRN

Azelaic acid and PDRN form an exceptionally well-matched combination for skin conditions where inflammation, hyperpigmentation, and impaired tissue quality coexist — most notably rosacea, acne with post-inflammatory hyperpigmentation, and melasma. PDRN addresses the tissue-regeneration deficit by activating the adenosine A2A receptor on fibroblasts, stimulating collagen synthesis, increasing vascular endothelial growth factor (VEGF) for improved tissue perfusion, and suppressing pro-inflammatory cytokines through the cAMP/PKA pathway. Azelaic acid complements this by providing targeted antibacterial control of C. acnes (reducing the bacterial trigger for inflammatory acne), selectively inhibiting tyrosinase in hyperactive melanocytes (preventing pigmentation without the bleaching risks of hydroquinone), and scavenging reactive oxygen species that would otherwise perpetuate the inflammatory cycle. The two ingredients attack skin dysfunction from fundamentally different angles: PDRN rebuilds and regenerates the dermal infrastructure, while azelaic acid corrects the surface-level manifestations of bacterial overgrowth, oxidative stress, and melanocyte hyperactivity. For rosacea specifically, this combination is particularly valuable. PDRN's A2A receptor-mediated anti-inflammatory action reduces the chronic dermal inflammation and vascular dysregulation underlying rosacea, while azelaic acid (FDA-approved for rosacea at 15%) reduces papulopustular lesions, erythema, and the oxidative damage that drives rosacea flares. Neither ingredient causes the photosensitivity, dryness, or irritation associated with retinoids or benzoyl peroxide, making the PDRN + azelaic acid protocol sustainable year-round for patients with reactive, rosacea-prone skin.

Clinical Data

Azelaic acid has extensive clinical evidence across acne, rosacea, and hyperpigmentation. For rosacea, a pivotal 2003 randomized controlled trial published in the Journal of the American Academy of Dermatology demonstrated that 15% azelaic acid gel (Finacea) produced a 58% reduction in inflammatory lesion count after 12 weeks, leading to its FDA approval for papulopustular rosacea. A 2011 Cochrane systematic review confirmed azelaic acid's efficacy for rosacea, noting that 15% azelaic acid was superior to metronidazole 0.75% for reducing inflammatory lesions. For acne, a 2010 meta-analysis of 14 trials found 20% azelaic acid comparable in efficacy to benzoyl peroxide 5%, tretinoin 0.05%, and erythromycin 2% — with significantly fewer side effects. For hyperpigmentation, a landmark 1991 double-blind study showed 20% azelaic acid produced comparable depigmentation to hydroquinone 4% in melasma patients over 24 weeks without ochronosis risk. A 2019 study in the Journal of Drugs in Dermatology confirmed that 15% azelaic acid significantly reduced MASI scores in melasma patients of Fitzpatrick types IV-VI. When combined with PDRN, the dual anti-inflammatory and regenerative approach addresses both the visible symptoms and the underlying tissue damage characteristic of chronic inflammatory skin conditions.

Product Formats in the Wild

Common ways this ingredient is delivered in clinical and consumer products.